Regeneron said the WHO Therapeutics Advisory Group recommended maftivimab, the most potent antibody in its Ebola treatment Inmazeb, for prioritized evaluation in clinical trials tied to the current Bundibugyo outbreak. The update is positive for Regeneron's Ebola franchise and may support broader clinical attention, but it is still an early-stage recommendation rather than a commercial or regulatory approval.
Regeneron said the WHO Therapeutics Advisory Group recommended maftivimab, the most potent antibody in its Ebola treatment Inmazeb, for prioritized evaluation in clinical trials tied to the current Bundibugyo outbreak. The update is positive for Regeneron's Ebola franchise and may support broader clinical attention, but it is still an early-stage recommendation rather than a commercial or regulatory approval.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
